Vantas (histrelin) is a depot formulation of a luteinising-hormone releasing hormone (LHRH) analogue. Inserted subcutaneously into the upper arm, the implant delivers an average of 50 micrograms of histrelin acetate daily for 12 months. Histrelin inhibits LH secretion leading to a fall in circulating testosterone levels promoting tumour regression and symptom improvement.
Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely monitored for exacerbation of symptoms during the first few weeks after Vantas implantation.
Further information: Orion